CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

CD40 immunotherapy shows efficacy in treating pancreatic cancer in mice and humans by eliciting antitumor immunity. Immunosuppressive tumor microenvironments can restrain antitumor immunity, particularly in pancreatic ductal adenocarcinoma (PDA). Because CD40 activation can reverse immune suppression and drive antitumor T cell responses, we tested the combination of an agonist CD40 antibody with gemcitabine chemotherapy in a small cohort of patients with surgically incurable PDA and observed tumor regressions in some patients. We reproduced this treatment effect in a genetically engineered mouse model of PDA and found unexpectedly that tumor regression required macrophages but not T cells or gemcitabine. CD40-activated macrophages rapidly infiltrated tumors, became tumoricidal, and facilitated the depletion of tumor stroma. Thus, cancer immune surveillance does not necessarily depend on therapy-induced T cells; rather, our findings demonstrate a CD40-dependent mechanism for targeting tumor stroma in the treatment of cancer.

[1]  J. Banchereau,et al.  CD40‐CD40 ligand , 2000, Journal of leukocyte biology.

[2]  K. Klinka,et al.  Indicator Plants of Coastal British Columbia , 1989 .

[3]  L. Zitvogel,et al.  The anticancer immune response: indispensable for therapeutic success? , 2008, The Journal of clinical investigation.

[4]  A. Nowak,et al.  Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. , 2003, Cancer research.

[5]  T. Dyke.  Finding the tumor copycat: Approximating a human cancer , 2010, Nature Medicine.

[6]  D. Tuveson,et al.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion. , 2007, Cancer research.

[7]  M. Glennie,et al.  CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help , 1999, Nature Medicine.

[8]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[9]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Thomas Müller-Reichert,et al.  Cortical Constriction During Abscission Involves Helices of ESCRT-III–Dependent Filaments , 2011, Science.

[11]  R. Vonderheide.  Prospect of Targeting the CD40 Pathway for Cancer Therapy , 2007, Clinical Cancer Research.

[12]  L. Grochow,et al.  Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  T. Schumacher,et al.  CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy , 1999, Nature Medicine.

[14]  Richard A. Flavell,et al.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling , 1998, Nature.

[15]  Polly Matzinger,et al.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.

[16]  Aaron Christ,et al.  Mixed Effects Models and Extensions in Ecology with R , 2009 .

[17]  K. Flaherty,et al.  Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  N. Van Rooijen,et al.  Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. , 1994, Journal of immunological methods.

[19]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[20]  B. Robinson,et al.  Immunotherapy and chemotherapy — a practical partnership , 2005, Nature Reviews Cancer.

[21]  D. Gabrilovich.  Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. , 2007, The Lancet. Oncology.

[22]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[23]  M. Willson,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011 .

[24]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[25]  H. Bien,et al.  Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40 , 1999, Nature Medicine.

[26]  Alberto Mantovani,et al.  Macrophages, innate immunity and cancer: balance, tolerance, and diversity. , 2010, Current opinion in immunology.